@article{4cf6afff4ff44c40b42091c116dc6e59,
title = "Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study",
abstract = "Next-generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene aberrations that have diagnostic and therapeutic significance. Here, we undertook a hospital-based prospective study (TOP-GEAR project, 2nd stage) to investigate the feasibility and utility of NGS-based analysis of 114 cancer-associated genes (the NCC Oncopanel test). We examined 230 cases (comprising more than 30 tumor types) of advanced solid tumors, all of which were matched with nontumor samples. Gene profiling data were obtained for 187 cases (81.3%), 111 (59.4%) of which harbored actionable gene aberrations according to the Clinical Practice Guidelines for Next Generation Sequencing in Cancer Diagnosis and Treatment (Edition 1.0) issued by 3 major Japanese cancer-related societies. Twenty-five (13.3%) cases have since received molecular-targeted therapy according to their gene aberrations. These results indicate the utility of tumor-profiling multiplex gene panel testing in a clinical setting in Japan. This study is registered with UMIN Clinical Trials Registry (UMIN 000011141).",
keywords = "NCC Oncopanel, actionable gene aberration, clinical sequencing, gene panel test, insurance reimbursement",
author = "Kuniko Sunami and Hitoshi Ichikawa and Takashi Kubo and Mamoru Kato and Yutaka Fujiwara and Akihiko Shimomura and Takafumi Koyama and Hiroki Kakishima and Mayuko Kitami and Hiromichi Matsushita and Eisaku Furukawa and Daichi Narushima and Momoko Nagai and Hirokazu Taniguchi and Noriko Motoi and Shigeki Sekine and Akiko Maeshima and Taisuke Mori and Reiko Watanabe and Masayuki Yoshida and Akihiko Yoshida and Hiroshi Yoshida and Kaishi Satomi and Aoi Sukeda and Taiki Hashimoto and Toshio Shimizu and Satoru Iwasa and Kan Yonemori and Ken Kato and Chigusa Morizane and Chitose Ogawa and Noriko Tanabe and Kokichi Sugano and Nobuyoshi Hiraoka and Kenji Tamura and Teruhiko Yoshida and Yasuhiro Fujiwara and Atsushi Ochiai and Noboru Yamamoto and Takashi Kohno",
note = "Funding Information: This work was supported in part by grants-in-aid from the Japan Agency for Medical Research and Development (AMED) (JP18kk0205004 and JP18lk1403003), and the National Cancer Center Research and Development Fund (27-A-1, 30-A-6, and NCC Biobank). The authors are grateful to Shunsuke Kondo, Shigehisa Kitano, Fumihiko Nakatani, Makoto Ohno, Koji Izutsu, Ayumu Arakawa, Kenjiro Namikawa, Aiko Maejima, Tomoyasu Kato, Seiichi Yoshimoto, Chiemi Kojima, Kimihiko Kawamura, Yasuo Shibuki, Kazuya Tokita, Mizuki Takatsu, Tadashi Kumamoto, Keiko Wakakuwa, Yuki Murai, Taro Shibata, and Aya Kuchiba (and to other physicians and staff at the National Cancer Center and other hospitals), who contributed to the TOP-GEAR project. We also thank staff at Riken Genesis, Sysmex, and Mitsui Knowledge Industry. Publisher Copyright: {\textcopyright} 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.",
year = "2019",
month = apr,
doi = "10.1111/cas.13969",
language = "English",
volume = "110",
pages = "1480--1490",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "4",
}
